Abstract: Antibody-drug conjugate (ADC), which conjugates cytotoxic drugs and monoclonal antibodies to reach target delivery of a potent payload, is an effective treatment for malignant tumor. ADC has been increasingly used for the treatment of tumors in a global context, but its drug-related adverse reactions have received more and more attention. Drug-induced liver injury (DILI) caused by ADC has become one of the most common adverse reactions, so more attention should be paid to the clinical treatment, in which corresponding measures should be taken on the basis of the degree of hepatic injury. This article is a retrospective analysis of the clinical manifestations, incidence rate and potential mechanism of ADC leading to liver injury, and a review of management after liver injury induced by ADC, aiming to provide reference for rational drug use of ADC in clinic.